A Phase I Safety and Tolerability Study of PP-001 Eye Drops in Healthy Adult Volunteers
Latest Information Update: 16 Jan 2024
At a glance
- Drugs KIO 101 (Primary)
- Indications Keratoconjunctivitis
- Focus Adverse reactions
- Sponsors Panoptes Pharma
- 25 May 2021 Status changed from active, no longer recruiting to completed, according to an EyeGate Pharma media release.
- 21 Dec 2020 According to an EyeGate Pharmaceuticals media release, Phase 1 safety data of this trial is completed.
- 10 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Jan 2021.